GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (NAS:SGMO) » Definitions » Beneish M-Score

Sangamo Therapeutics (Sangamo Therapeutics) Beneish M-Score : 0.26 (As of Apr. 25, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Sangamo Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 0.26 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Sangamo Therapeutics's Beneish M-Score or its related term are showing as below:

SGMO' s Beneish M-Score Range Over the Past 10 Years
Min: -4.67   Med: -1.79   Max: 2.78
Current: 0.26

During the past 13 years, the highest Beneish M-Score of Sangamo Therapeutics was 2.78. The lowest was -4.67. And the median was -1.79.


Sangamo Therapeutics Beneish M-Score Historical Data

The historical data trend for Sangamo Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangamo Therapeutics Beneish M-Score Chart

Sangamo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.78 -4.67 -1.97 -2.59 0.26

Sangamo Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.59 -0.16 -0.22 0.01 0.26

Competitive Comparison of Sangamo Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Sangamo Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sangamo Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sangamo Therapeutics's Beneish M-Score falls into.



Sangamo Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sangamo Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.1873+0.528 * 1+0.404 * 0.4514+0.892 * 1.5834+0.115 * 0.476
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6163+4.679 * 0.738108-0.327 * 1.8344
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $1.3 Mil.
Revenue was 2.042 + 9.398 + 6.835 + 157.957 = $176.2 Mil.
Gross Profit was 2.042 + 9.398 + 6.835 + 157.957 = $176.2 Mil.
Total Current Assets was $94.3 Mil.
Total Assets was $165.3 Mil.
Property, Plant and Equipment(Net PPE) was $52.9 Mil.
Depreciation, Depletion and Amortization(DDA) was $22.2 Mil.
Selling, General, & Admin. Expense(SGA) was $61.2 Mil.
Total Current Liabilities was $47.7 Mil.
Long-Term Debt & Capital Lease Obligation was $33.5 Mil.
Net Income was -60.295 + -104.163 + -114.506 + 21.133 = $-257.8 Mil.
Non Operating Income was -0.296 + -44.799 + -51.347 + -58.571 = $-155.0 Mil.
Cash Flow from Operations was -50.538 + -47.293 + -60.711 + -66.3 = $-224.8 Mil.
Total Receivables was $4.5 Mil.
Revenue was 27.23 + 26.46 + 29.378 + 28.231 = $111.3 Mil.
Gross Profit was 27.23 + 26.46 + 29.378 + 28.231 = $111.3 Mil.
Total Current Assets was $300.3 Mil.
Total Assets was $562.5 Mil.
Property, Plant and Equipment(Net PPE) was $125.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $20.6 Mil.
Selling, General, & Admin. Expense(SGA) was $62.7 Mil.
Total Current Liabilities was $111.7 Mil.
Long-Term Debt & Capital Lease Obligation was $39.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1.326 / 176.232) / (4.472 / 111.299)
=0.007524 / 0.04018
=0.1873

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(111.299 / 111.299) / (176.232 / 176.232)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (94.328 + 52.865) / 165.32) / (1 - (300.327 + 125.533) / 562.509)
=0.109648 / 0.242928
=0.4514

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=176.232 / 111.299
=1.5834

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(20.562 / (20.562 + 125.533)) / (22.192 / (22.192 + 52.865))
=0.140744 / 0.295669
=0.476

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(61.167 / 176.232) / (62.682 / 111.299)
=0.347082 / 0.563186
=0.6163

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((33.515 + 47.731) / 165.32) / ((38.986 + 111.711) / 562.509)
=0.491447 / 0.267901
=1.8344

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-257.831 - -155.013 - -224.842) / 165.32
=0.738108

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sangamo Therapeutics has a M-score of 0.26 signals that the company is likely to be a manipulator.


Sangamo Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Sangamo Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sangamo Therapeutics (Sangamo Therapeutics) Business Description

Traded in Other Exchanges
Address
7000 Marina Boulevard, Brisbane, CA, USA, 94005
Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.
Executives
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Beers Courtney director C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
Margaret A Horn director 925 PAGE MILL ROAD, PALO ALTO CA 94304
Nathalie Dubois-stringfellow officer: SVP-Chief Development Officer C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
John Markels director C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
H Stewart Parker director
Biogen Ma Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Scott B. Willoughby officer: SVP, Gen. Counsel & Secretary 7000 MARINA BLVD, BRISBANE CA 94005
Gary Loeb officer: EVP & General Counsel 5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608
Jason D. Fontenot officer: SVP, Chief Scientific Officer 7000 MARINA BLVD, BRISBANE CA 94005
Robert J. Schott officer: SVP, Head of Development 7000 MARINA BLVD, BRISBANE CA 94005
Rolf Andrew Ramelmeier officer: EVP, Technical Operations 7000 MARINA BLVD, BRISBANE CA 94005
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Kenneth J. Hillan director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
David Mark Mcclung officer: EVP Chief Business Officer 7000 MARINA BLVD, BRISBANE CA 94005

Sangamo Therapeutics (Sangamo Therapeutics) Headlines

From GuruFocus